MARKET

IMVT

IMVT

Immunovant Inc
NASDAQ
14.46
+0.54
+3.88%
Pre Market: 14.34 -0.12 -0.83% 08:02 05/19 EDT
OPEN
13.99
PREV CLOSE
13.92
HIGH
14.52
LOW
13.71
VOLUME
805
TURNOVER
0
52 WEEK HIGH
34.47
52 WEEK LOW
12.72
MARKET CAP
2.46B
P/E (TTM)
-5.5296
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IMVT last week (0512-0516)?
Weekly Report · 9h ago
Weekly Report: what happened at IMVT last week (0505-0509)?
Weekly Report · 05/12 09:24
Argenx Q1 Earnings: Less Than Perfect Report Gets Punished
Seeking Alpha · 05/09 12:02
Weekly Report: what happened at IMVT last week (0428-0502)?
Weekly Report · 05/05 09:24
Weekly Report: what happened at IMVT last week (0421-0425)?
Weekly Report · 04/28 09:26
Gran Tierra, Immunovant, AIM, Cracker Barrel, JB Hunt: Insider Moves Unveiled!
TipRanks · 04/26 13:03
Insider Moves: Immunovant Executives Cash In on Stocks
TipRanks · 04/26 02:04
Immunovant’s Strategic Leadership and Portfolio Expansion Justify Buy Rating
TipRanks · 04/23 06:37
More
About IMVT
Immunovant, Inc. is a clinical-stage immunology company. The Company is focused on developing treatments for patients with autoimmune diseases. Its product pipeline includes batoclimab and IMVT-1402, both of which are novel, fully human monoclonal antibodies that target the neonatal fragment crystallizable receptor (FcRn). Batoclimab is a subcutaneous injection with dosing. Batoclimab is observed to reduce immunoglobulin G (IgG) antibodies that cause inflammation and disease. Its product candidate, batoclimab, is dosed in small volumes and with a 27-gauge needle. It is developing batoclimab for myasthenia gravis (MG), thyroid eye disease (TED), chronic inflammatory demyelinating polyneuropathy (CIDP) and Graves’ disease (GD). Its lead product candidate IMVT-1402 has also been observed to reduce IgG antibody levels in a Phase I clinical trial conducted in healthy adults. IMVT-1402 is a fully human monoclonal antibody that inhibits FcRn.

Webull offers Immunovant Inc stock information, including NASDAQ: IMVT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMVT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMVT stock methods without spending real money on the virtual paper trading platform.